FDA And FTC Join Forces On Biosimilars

Teaming Up To Eliminate Barriers To Biosimilar Competition

Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.

Conceptual business illustration with the words anti-competitive practices
FDA and FTC to target anticompetitive behavior that impedes access to biosimilars • Source: Shutterstock

Biologic manufacturers could face a wave of enforcement actions against behavior that impedes the marketing of biosimilars as the US Food and Drug Administration and Federal Trade Commission are teaming up to promote competition in biologics markets.

The two agencies issued a 3 February joint statement in which they committed to strengthening efforts to curtail and...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.